Tuesday, July 1, 2025 7/1/2025

Dr. Kim R50 Research Specialist Clinician 2022

Award Number: R50CA276015
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/10/2023
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Dr. Kim R50 Research Specialist Clinician 2022 - Abstract Dr. Kim is an active and vital leader in the clinical trials program at The University of Michigan Rogel Cancer Center whose extensive, collaborative work has supported the NCI clinical trials infrastructure institutionally and nationally. Her key contributions to the mission and conduct of NCI-sponsored clinical trials include: 1) Institutional leadership of the Cancer Center Neuro-Oncology clinical research group and institutional Protocol Review Committee; 2) Serving as site Principal Investigator and central study team member for NCI-funded clinical trials; 3) National leadership as Co-Chair of the NIH/NCI Brain Metastases Interest Group and active member of NRG and Alliance Brain Tumor Committees; 4) National leadership in implementing practice- changing findings from NCI-funded clinical trials as member of the NCCN Guidelines CNS Cancers Committee and Senior Associate Editor of her specialty’s primary journal. Dr. Kim is an active investigator who has contributed 165 patient enrollments to interventional treatment and non-treatment (supportive and observational) trials since 2015, and has served as Principal Investigator of 5 investigator-initiated studies which she has developed and conducted. A recently completed trial is now in development as a multi-site study through the NRG Brain Tumor Committee. She has helped lead institutional and national efforts to broaden trial eligibility for underrepresented demographic and disease populations. Through the support of the Research Specialist Award, Dr. Kim proposes to advance the institutional clinical research mission, and to establish her research and national leadership contribution to NCI funded clinical trials. To address the Cancer Center’s objectives to increase accrual to interventional trials overall, and to increase institutional accrual of minorities and women, Dr. Kim proposes to launch a screening program across the entire Cancer Center to identify and enroll trial-eligible patients for CNS metastases-related trials (NCI-funded trials which have had suboptimal accrual). To expand the catchment of a more diverse patient population from the broader oncology community, she proposes to partner with University of Michigan affiliated community sites to develop streamlined processes for multi-site collaboration, launch a University of Michigan Network virtual tumor board to discuss cases and trial options, distribute newsletters and conduct CME events to increase awareness and participation in NCI-funded and investigator-initiated trials. She will finalize and conduct as Principal Investigator the initial phase of a developing Phase II/III Trial through NRG Oncology investigating an imaging biomarker to personalize radiotherapy in patients with glioblastoma. She will facilitate new inter-institutional collaborations and launch research initiatives as Co-Chair of the NIH/NCI Brain Metastases Interest Group, and will further advance in her participation and national leadership in support of NCI-funded clinical research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $171,684 )
2025	2025	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE STE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Cause and Prevention Research	000	3	2/13/2025	NON-COMPETING CONTINUATION	$171,684
														Subtotal = $171,684

Issue Date FY: 2024 ( Subtotal = $171,684 )
2024	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Cause and Prevention Research	000	2	3/15/2024	NON-COMPETING CONTINUATION	$171,684
														Subtotal = $171,684

Issue Date FY: 2023 ( Subtotal = $171,684 )
2023	2023	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON STREET	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Cause and Prevention Research	000	1	3/9/2023	NEW	$171,684
														Subtotal = $171,684

Grand Total All Awards = $515,052

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dr. Kim R50 Research Specialist Clinician 2022

Award Number: R50CA276015

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/10/2023

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer